MedDataX Logo

Aripiprazole Open-Label, Safety and Tolerability Study

NCT ID: NCT00102518

Last Updated: 2012-08-31

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

325 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-09-30

Study Completion Date

2007-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to test the long-term safety and tolerability of aripiprazole in adolescent patients with schizophrenia, and child and adolescent patients with bipolar I disorder, manic or mixed episode.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.

NCT01122927

Adolescent Schizophrenia Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features
TERMINATED PHASE3

Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia

NCT02050854

Bipolar 1 Disorder Schizophrenia Mental Disorder +1 more
COMPLETED

Aripiprazole in Patients With Acute Mania

NCT00095511

Bipolar Disorder
COMPLETED PHASE3

Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode

NCT00080314

Bipolar Disorder
COMPLETED PHASE3

Aripiprazole in Children and Adolescents With Bipolar I Disorder

NCT00110461

Bipolar Disorder
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia Bipolar Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NCT00102063 and NCT00110461 Subjects

All subjects had either completed or had withdrawn from the double-blind extension phase of study NCT00110461 (OPDC 31-03-240) and study NCT00102063 (OPDC 31-03-239).

Group Type EXPERIMENTAL

Aripiprazole

Intervention Type DRUG

2 to 30 mg/day orally (2, 5, 10, 15, 20, 25, or 30 mg/day); tablets in strengths of 2, 5, 10, and 15 mg were used to achieve desired doses

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aripiprazole

2 to 30 mg/day orally (2, 5, 10, 15, 20, 25, or 30 mg/day); tablets in strengths of 2, 5, 10, and 15 mg were used to achieve desired doses

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

OPC-14597

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adolescent patients with schizophrenia, or child and adolescent patients with bipolar I disorder, manic or mixed episode

Exclusion Criteria

* Patients with a co-morbid serious, uncontrolled systemic illness
* Patients with a significant risk of committing suicide
Minimum Eligible Age

10 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Local Institution

Birmingham, Alabama, United States

Site Status

Local Institution

Little Rock, Arkansas, United States

Site Status

Local Institution

Costa Mesa, California, United States

Site Status

Local Institution

Fresno, California, United States

Site Status

Local Institution

Orange, California, United States

Site Status

Local Institution

Riverside, California, United States

Site Status

Local Institution

Rosemead, California, United States

Site Status

Local Institution

Sacramento, California, United States

Site Status

Local Institution

Temecula, California, United States

Site Status

Local Institution

Washington D.C., District of Columbia, United States

Site Status

Local Institution

Altamonte Springs, Florida, United States

Site Status

Local Institution

Fort Lauderdale, Florida, United States

Site Status

Local Institution

Hialeah, Florida, United States

Site Status

Local Institution

Jacksonville, Florida, United States

Site Status

Local Institution

Miami, Florida, United States

Site Status

Local Institution

Orange City, Florida, United States

Site Status

Local Institution

Tampa, Florida, United States

Site Status

Local Institution

Atlanta, Georgia, United States

Site Status

Local Institution

Honolulu, Hawaii, United States

Site Status

Local Institution

Chicago, Illinois, United States

Site Status

Local Institution

Kansas City, Kansas, United States

Site Status

Local Institution

Lexington, Kentucky, United States

Site Status

Local Institution

Louisville, Kentucky, United States

Site Status

Local Institution

Lake Charles, Louisiana, United States

Site Status

Local Institution

Metairie, Louisiana, United States

Site Status

Local Institution

New Orleans, Louisiana, United States

Site Status

Local Institution

Somerville, Massachusetts, United States

Site Status

Local Institution

Clinton, Michigan, United States

Site Status

Local Institution

Kansas City, Missouri, United States

Site Status

Local Institution

Saint Charles, Missouri, United States

Site Status

Local Institution

Elmsford, New York, United States

Site Status

Local Institution

New York, New York, United States

Site Status

Local Institution

Olean, New York, United States

Site Status

Local Institution

Rochester, New York, United States

Site Status

Local Institution

Chapel Hill, North Carolina, United States

Site Status

Local Institution

Cleveland, Ohio, United States

Site Status

Local Institution

Lyndhurst, Ohio, United States

Site Status

Local Institution

Oklahoma City, Oklahoma, United States

Site Status

Local Institution

Bala-Cynwyd, Pennsylvania, United States

Site Status

Local Institution

Philadelphia, Pennsylvania, United States

Site Status

Local Institution

Memphis, Tennessee, United States

Site Status

Local Institution

Bellaire, Texas, United States

Site Status

Local Institution

DeSoto, Texas, United States

Site Status

Local Institution

Houston, Texas, United States

Site Status

Local Institution

San Antonio, Texas, United States

Site Status

Local Institution

Salt Lake City, Utah, United States

Site Status

Local Institution

Kirkland, Washington, United States

Site Status

Local Institution

Seattle, Washington, United States

Site Status

Local Institution

Spokane, Washington, United States

Site Status

Local Institution

Wauwatosa, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

31-03-241

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Aripiprazole Pharmacokinetics (PK) and Tolerability Study in Children and Adolescents
NCT00102479 COMPLETED PHASE2
Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder
NCT00216723 COMPLETED
An Open-Label Trial of Aripiprazole in Children and Adolescents With Bipolar Disorder
NCT00221416 COMPLETED PHASE3
Study of Aripiprazole in Patients With Bipolar I Disorder
NCT00257972 COMPLETED PHASE3
A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder
NCT04030143 COMPLETED PHASE1/PHASE2
Aripiprazole for the Treatment of Mania in Children and Adolescents With Bipolar Disorder
NCT00181779 COMPLETED PHASE4
Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials
NCT00239356 COMPLETED PHASE3
A Multicenter Investigative Study of the Safety and Efficacy of Long-term Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode
NCT00606229 COMPLETED PHASE3
Study of Aripiprazole in the Treatment of Patients With Acute Symptoms in Bipolar Disorder
NCT00036101 COMPLETED PHASE3
Study of Aripiprazole in Patients With a History of Bipolar Disorder
NCT00036348 COMPLETED PHASE3
Drug-drug Interaction Study of Aripiprazole and Lamotrigine in Patients With Bipolar Type I Disorder
NCT00321516 COMPLETED PHASE1
Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)
NCT00365859 COMPLETED PHASE3
A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode
NCT00094432 COMPLETED PHASE3
A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode
NCT00338273 WITHDRAWN PHASE3
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group-comparison Trial of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode
NCT00606281 COMPLETED PHASE3
Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder
NCT01710709 COMPLETED PHASE3
A Multicenter, Investigative Study of the Safety and Efficacy of Extended Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode
NCT00606320 COMPLETED PHASE3
Aripiprazole Treatment of Bipolar Depression
NCT00198198 COMPLETED PHASE4
A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode
NCT00277212 COMPLETED PHASE4
A Multicenter, Placebo-controlled, Double-blind Investigative Extension Trial of the Safety and Efficacy of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode
NCT00606177 COMPLETED PHASE3
Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients
NCT01567527 COMPLETED PHASE3
Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)
NCT00332241 COMPLETED PHASE3
Aripiprazole in the Treatment of Bipolar Depression
NCT00226317 COMPLETED NA
A Study of Aripiprazole in Patients With Major Depressive Disorder
NCT00105196 COMPLETED PHASE3
Study of Aripiprazole in the Treatment of Patients With Acute Symptoms of Bipolar Disorder
NCT00046384 COMPLETED PHASE3